News
CAPR
--
0.00%
--
The Daily Biotech Pulse: Amag Spikes On Takeover Rumors, Zosano Wilts On Regulatory Setback, Pulmonx Makes Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)
Benzinga · 10/01 12:18
The Week Ahead In Biotech: FDA Decisions For Mesoblast And Eton, Coronavirus Vaccine Updates
Biotech stock reversed course last week, dragged lower by the broader market weakness.
Benzinga · 09/26 18:40
American Well, MediciNova among major healthcare gainers, AC Immune, Wave Life Sciences leads losers' pack
Gainers: American Well (AMWL) +17%, MediciNova (MNOV) +13%, Mallinckrodt (MNK) +7%, Capricor Therapeutics (CAPR) +8%, Adamas Pharmaceuticals (ADMS) +6%.Losers: AC Immune (ACIU) -42%, Wave Life Sciences (WVE) -34%, Rockwell Medical (RMTI) -28%, Aurora Cannabis (ACB) -23%, NanoVibronix NAOV -15%.
Seekingalpha · 09/23 14:56
Capricor Therapeutics Reports Will Present Results From HOPE-2 Trial With CAP-1002 In Duchenne Muscular Dystrophy At International World Muscle Society Virtual Congress 2020 Oct. 1 At 12:30 p.m. EDT
Capricor Therapeutics, Inc. (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced
Benzinga · 09/23 13:27
Capricor Therapeutics to Present Results from the HOPE-2 Trial with CAP-1002 in Duchenne Muscular Dystrophy at the International World Muscle Society Virtual Congress 2020
\--Final 12-Month Results from Phase II Trial to be Presented on October 1--LOS ANGELES, Sept. 23, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment
GlobeNewswire · 09/23 13:25
Capricor Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
LOS ANGELES, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, announced today that Linda Marbán, Ph.D
GlobeNewswire · 09/10 14:15
LD Micro: 360 Companies--Set to Present this Week.
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.
ACCESSWIRE · 09/01 21:34
Capricor Therapeutics to Present at The LD 500 Virtual Conference
LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / Capricor Therapeutics ("Capricor") (NASDAQ:CAPR), a clinical-stage biotechnology company focused on the development of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases, today announced that it will
ACCESSWIRE · 08/31 14:00
Capricor Therapeutics Inc Unit, Cedars-Sinai Medical Center Entered Into Amendment To Exclusive License Agreement
-Reuters
Reuters · 08/25 20:36
Why Capricor Therapeutics Is Trading Higher Today
Capricor Therapeutics (NASDAQ: CAPR) shares are trading higher on Tuesday after the company announced the U.S. Food and Drug Administration has accepted its investigational new drug application for a Phase 2 clinical trial of CAP-1002 in patients with COVID-19
Benzinga · 08/25 15:34
Capricor Therapeutics Announces U.S. FDA Acceptance of its IND Application for a Phase 2 Clinical Trial of CAP-1002 in Patients with COVID-19
– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 –– The Study Leverages Capricor’s Lead Asset, CAP-1002 Technology –LOS ANGELES, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (“Capricor”) (NASDAQ
GlobeNewswire · 08/25 14:15
Capricor on go with mid-stage study of CAP-1002 in COVID-19
The FDA has signed off on a Phase 2 clinical trial, INSPIRE, evaluating Capricor Therapeutics' (CAPR +3.7%) lead candidate CAP-1002 in COVID-19 patients re
Seeking Alpha - Article · 08/25 14:10
Capricor Therapeutics Announces FDA Acceptance Of Its IND Application For A Phase 2 Clinical Trial Of CAP-1002 In Patients With COVID-19
– The INSPIRE Trial is a Randomized, Placebo-Controlled, Multi-Center Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 – –The Study Leverages Capricor's Lead Asset,
Benzinga · 08/25 13:17
Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q2 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 08/09 10:22
GRPN, CNDT, AYX and CAPR among midday movers
Seeking Alpha - Article · 08/07 16:39
Earnings-related names dominate premarket losers
Seeking Alpha - Article · 08/07 12:18
Earnings movers dominate premarket losers list
Seeking Alpha - Article · 08/07 12:18
Capricor Therapeutics EPS beats by $0.11
Capricor Therapeutics (NASDAQ:CAPR): Q2 GAAP EPS of -$0.23 beats by $0.11. Revenue of $0.05M (-87.8% Y/Y) Cash, cash equivalents and marketable securities
seekingalpha · 08/07 01:05
Capricor Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
GlobeNewswire · 08/06 21:01
Capricor Therapeutics Shares Spike Higher After Study Co. Sponsored Was Published Titled 'European Heart Journal: Cell Infusions Benefit Heart Patients'
https://www.cedars-sinai.org/newsroom/european-heart-journal-cell-infusions-benefit-heart-patients/
Benzinga · 08/04 14:37
Webull provides a variety of real-time CAPR stock news. You can receive the latest news about Capricor through multiple platforms. This information may help you make smarter investment decisions.
About CAPR
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.
More